EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial

Rodney Sinclair, Natasha Mesinkovska, Debanjali Mitra, Dalia Wajsbrot, Ernest H Law, Robert Wolk, Brett King

American Journal of Clinical Dermatology · 2025

DOI: 10.1007/s40257-024-00899-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Clinical Dermatology, 2025. Verfasst von Rodney Sinclair und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sinclair Dermatology, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The ALLEGRO phase 2b/3 study investigated the efficacy and safety of ritlecitinib in patients with alopecia areata (AA). OBJECTIVE: To describe the impact of ritlecitinib on patient-reported hair loss using the Alopecia Areata Patient Priority Outcomes (AAPPO) instrument and evaluate the relationship between clinically meaningful hair regrowth and improvements in patient-reported impacts. METHODS: In ALLEGRO-2b/3, patients aged ≥ 12 years with AA and ≥ 50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (± 4-week 200-mg daily loading dose), 10 mg, or placebo for 24 weeks and then continued ritlecitinib or switched from placebo to ritlecitinib 200/50 or 50 mg for 24 weeks. The AAPPO instrument evaluated improvement in hair loss, emotional symptoms (ES), and activity limitations (AL) from weeks 4 to 48 (secondary endpoint). Mean changes in ES and AL domain scores and individual items at weeks 24 and 48 were calculated for Severity of Alopecia Tool (SALT) score ≤ 20 responders and nonresponders (exploratory endpoint). RESULTS: Overall, 718 patients were randomized. At week 24, 5-36% of patients receiving ritlecitinib 10-200/50 mg reported improvement in scalp hair loss versus 9% receiving placebo. The results for eyebrow, eyelash, and body hair loss were similar. Mean change from baseline in ES and AL scores at weeks 24 and 48 was small and similar between groups. Mean change was larger for individual hair loss and ES items at weeks 24 and 48 in SALT score ≤ 20 responders versus nonresponders. CONCLUSIONS: The AAPPO instrument demonstrated the beneficial impact of ritlecitinib on patient-reported hair growth, which was consistent with improvements in clinician-reported outcomes. CLINICAL TRIAL REGISTRATION: NCT03732807. INFOGRAPHIC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataHumansFemalePatient Reported Outcome MeasuresMaleAdultMiddle AgedTreatment OutcomeYoung AdultDouble-Blind MethodHairAdolescentDose-Response Relationship, DrugSeverity of Illness IndexChild

Autor:innen und Institutionen

  • Sinclair Dermatology, Melbourne, VIC, Australia.
  • UC Irvine School of Medicine, Irvine, CA, USA.
  • Pfizer Inc, New York, NY, USA.
  • Pfizer Inc, New York, NY, USA. ernest.law@pfizer.com.
  • Pfizer Inc, Groton, CT, USA.
  • Yale School of Medicine, New Haven, CT, USA.

Förderung

  • NCATS NIH HHS
  • Pfizer

Zitieren

APA

Sinclair, R., Mesinkovska, N., Mitra, D., Wajsbrot, D., Law, E. H., Wolk, R., & King, B. (2025). Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-024-00899-4

Vancouver

Sinclair R, Mesinkovska N, Mitra D, Wajsbrot D, Law EH, Wolk R, et al. Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial. American Journal of Clinical Dermatology. 2025. doi:10.1007/s40257-024-00899-4

BibTeX
@article{Sinclair2025,
  author = {Sinclair, Rodney and Mesinkovska, Natasha and Mitra, Debanjali and Wajsbrot, Dalia and Law, Ernest H and Wolk, Robert and King, Brett},
  title = {Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial},
  journal = {American Journal of Clinical Dermatology},
  year = {2025},
  doi = {10.1007/s40257-024-00899-4}
}
Kostenlos starten →